文献速递衰弱、肌少症与跌倒老年慢病共病管理

每日低剂量阿司匹林对健康老年人白质高信号与视网膜血管口径的影响:ASPREE 的 ENVIS-ion 探索性神经影像亚组研究

The effects of daily low-dose aspirin on white matter hyperintensity lesions and retinal vascular calibre in healthy older adults: the ENVIS-ion exploratory neuroimaging substudy of the ASPREE randomised clinical trial.
PubMed 文献 · Lancet Healthy Longev · 2026-02-14

参与者随机接受每日肠溶阿司匹林 100 mg 或安慰剂,并在基线与 3 年后接受脑 MRI 与眼底照相。结果显示阿司匹林组深部白质高信号占比增加更多,但总白质高信号与脑室周围白质高信号变化及视网膜血管口径均无组间差异,且 ASPREE 中阿司匹林组大出血发生率更高。

要点

  • 3 年内低剂量阿司匹林未减缓白质高信号总体进展,也未改善视网膜血管口径。

核心结论

  • 在健康老年人中,低剂量阿司匹林对白质高信号进展和视网膜血管口径均无获益,且大出血风险更高。

研究设计与样本

  • ENVIS-ion 为 ASPREE 双盲随机对照试验中预先设计的探索性神经血管亚组研究。
  • ASPREE 共纳入 19 114 名基线无心血管疾病、卒中或认知障碍的老年人(≥70 岁)。
  • ENVIS-ion 从澳大利亚两个临床试验中心纳入 610 人,随机分配至每日肠溶阿司匹林 100 mg 组(312 人)或安慰剂组(298 人)。
  • 参与者在基线与 3 年后接受脑 MRI 和眼底照相,图像由对分组不知情的评估者判读。
  • 采用线性模型分析白质高信号体积(占总脑体积百分比)与视网膜血管口径的变化。

主要发现

  • 未发现阿司匹林对视网膜血管口径有影响的证据。

关键数值与推荐

  • 阿司匹林干预为每日肠溶阿司匹林 100 mg,对照为匹配安慰剂。
  • 入组人群为年龄 ≥70 岁、基线无心血管疾病、卒中或认知障碍的老年人。
  • 影像随访时间为基线与 3 年。
  • 主要结局为总白质高信号与区域白质高信号体积(占总脑体积百分比)及视网膜血管口径的变化。

临床怎么用

  • 对无心血管疾病的健康老年人,不应以延缓脑小血管病或视网膜血管改变为目的处方低剂量阿司匹林。
  • 与老年人讨论阿司匹林一级预防时,需权衡本研究中观察到的大出血风险升高。
  • 白质高信号与视网膜血管口径不宜作为评估阿司匹林疗效的监测指标。

局限性

  • 本研究为探索性亚组研究,仅纳入澳大利亚两个中心的 610 名参与者。
  • 随访影像仅覆盖 3 年,未评估更长期影响。
  • 大出血数据来自 ASPREE 主研究,并非 ENVIS-ion 亚组本身。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cerebral small vessel disease and alterations in retinal vascular calibre (RVC) are recognised precursors of stroke, dementia, and cognitive decline. We aimed to assess the effect of low-dose aspirin on white matter hyperintensity (WMH), a marker of cerebral small vessel disease, and changes in RVC. METHODS: We conducted a prospectively planned exploratory neurovascular substudy (ENVIS-ion) of the Aspirin in Reducing Events in the Elderly (ASPREE) double-blinded randomised clinical trial of 19 114 older adults (aged ≥70 years), who had no previous cardiovascular disease, stroke, or cognitive impairment at baseline. Participants were allocated to daily enteric-coated aspirin 100 mg or matching placebo using computer-generated randomisation and underwent MRI of the brain and fundus photography at two clinical trials sites in Australia at baseline and after 3 years. WMH and RVC measures were assessed by graders blinded to study treatment allocation. The effects of aspirin on total and regional WMH volumes (as a percentage of total brain volume) and RVC over time were analysed using linear models. ASPREE is registered with ClinicalTrials.gov, NCT01038583, and the International Standard Randomised Controlled Trial Number Registry, ISRCTN83772183. FINDINGS: Between April, 2010, and April, 2012, 610 participants from the eligible ASPREE cohort of 2346 individuals were enrolled in the ENVIS-ion substudy. Of the 610 participants (mean age 75·2 years [SD 4·1], 289 [47%] male and 321 [53%] female), 312 were assigned to receive aspirin and 298 to placebo. Over 3 years, the aspirin group had a greater increase in the percentage of deep WMH (β 0·14 [95% CI 0·01 to 0·27]) but there was no difference between aspirin and placebo groups in changes from baseline to 3 years in total brain WMH (0·05 [-0·02 to 0·11]) or periventricular WMH (0·03 [-0·03 to 0·09]). There was no evidence of an aspirin effect on RVC. The rate of major haemorrhage was higher in the aspirin arm for the ASPREE study (hazard ratio 1·38, 95% CI 1·18 to 1·62). INTERPRETATION: In this exploratory study, there was no evidence that low-dose aspirin in healthy older adults had any effect on RVC or attenuated the progression of WMH during a 3-year period. FUNDING: National Health and Medical Research Council of Australia.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Abhayaratna WP, Reid CM, Webb KL, et al. The effects of daily low-dose aspirin on white matter hyperintensity lesions and retinal vascular calibre in healthy older adults: the ENVIS-ion exploratory neuroimaging substudy of the ASPREE randomised clinical trial. Lancet Healthy Longev. 2026. PMID: 41698380. doi:10.1016/j.lanhl.2025.100815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。